Want to see ECVT full AI Analyst Report?
EarningsQ2 2026 Earnings Report
ECVT Q2 2026 EPS Results
Actual EPS$0.21
Consensus EPS$0.19
Beat/MissBeat by +$0.02
One Year Ago EPS$0.12
ECVT Q2 2026 Revenue Results
Actual Revenue$249.96M
Expected Revenue$237.54M
Beat/MissBeat by +$12.42M
YoY Revenue Growth+24.90%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
ECVT Upcoming Earnings
Ecovyst's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
ECVT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong operational execution and financial performance: Q2 sales and adjusted EBITDA grew materially (sales up $74M; EBITDA up 27%), management closed an accretive bolt-on acquisition (Calabrian) with immediate contribution and synergies, raised full-year guidance for revenue, adjusted EBITDA and free cash flow, and maintained liquidity and a disciplined capital allocation plan. Offsetting risks include elevated sulfur costs that increase working capital and a $100M acquisition-related debt add-on that raised leverage to 2.0x, near-term higher turnaround and manufacturing costs, and potential demand sensitivity if sulfur prices remain elevated. Overall, the positive operational results, accretive M&A and upgraded guidance outweigh the manageable near-term cost and market risks.Company Guidance
Revenue Growth and Top-Line Metrics
Second quarter sales of $250 million, up $74 million year-over-year; excluding a $55 million sulfur cost pass-through, sales were up nearly 11% reflecting higher regenerated and virgin sulfuric acid volumes and favorable contractual pricing.
Strong Adjusted EBITDA Performance
Adjusted EBITDA of $53 million in Q2, up 27% versus Q2 2025 and solidly within guidance; excluding pass-through effects, adjusted EBITDA was up approximately $11 million driven by volume and pricing.
Raised Full-Year Adjusted EBITDA Guidance
Full year 2026 adjusted EBITDA guidance increased to $195 million–$207 million (incorporating Calabrian); legacy business guidance tightened to $185 million–$195 million, reflecting confidence in demand stability and performance.
Accretive Bolt-On Acquisition (Calabrian)
Closed Calabrian acquisition on June 30; adds sulfur dioxide and derivative chemistries, expected to be accretive from day 1 with second-half 2026 adjusted EBITDA contribution of $10 million–$12 million and targeted cost/revenue synergies of $3 million–$4 million (purchase multiple ~8x stepping down to ~7x after synergies).
Volume Growth Drivers
Regenerated sulfuric acid volumes increased on high refinery utilization and favorable alkylate economics; virgin sulfuric acid volumes increased on a double-digit percentage basis year-over-year, aided by the May 2025 Waggaman acquisition.
Cash Flow, Liquidity and Capital Allocation
Positive cash generation in Q2; adjusted free cash flow of $13 million for the first half of 2026. Ended Q2 with available liquidity of $176 million ($88 million cash + $88 million revolver availability). Over past 15 months: $83 million stock repurchases, $472 million debt reduction, and $224 million on 2 bolt-on acquisitions.
Upgraded Free Cash Flow and Balanced Capital Plan
Full-year adjusted free cash flow guidance raised to $45 million–$55 million (from $40M–$55M), while maintaining flexibility to fund organic projects (~$20 million Gulf Coast expansion), bolt-ons, debt reduction and buybacks.
Integration and Operational Execution
Calabrian integration reported on plan after one month with leadership retained and no customer disruptions; Gulf Coast storage and logistics expansion underway to support growing virgin sulfuric acid demand.
ECVT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed